phosphatidylinositol 4-kinase type 2 alphaGenealiases: NEDMSB · PI4KII · PIK42A
Q-omics provides the consensus-scored PI4K2A profile across patient tissues and cancer cell-line models. PI4K2A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PI4K2A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, PI4K2A RNA expression shows 19,657 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where PI4K2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PI4K2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PI4K2A survival associations across molecular data types. PI4K2A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PI4K2A RNA expression–survival associations across cancer types. High PI4K2A expression shows unfavorable associations in ACC, HNSC and COAD, but favorable associations in SCLC, UCEC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PI4K2A RNA expression.
This table summarizes PI4K2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PI4K2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PI4K2A shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, THCA, LIHC and COAD. The HNSC box plot shows higher PI4K2A RNA expression in tumor versus normal tissue (log2 FC = +1.064, t-test p < 0.001).
This table shows molecular features associated with PI4K2A in patient tissues and cancer cell lines. In patient samples, PI4K2A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PI4K2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
